Radiopharmaceuticals for Positron Emission Tomography in Dementia Diagnosis
DOI:
https://doi.org/10.14738/bjhr.1206.19664Keywords:
radiopharamaceuticals, positrom emission tomography, dementiaAbstract
Positron emission tomography (PET) is a method of nuclear medical imaging which, using molecules traced by the positron radionuclides (radiopharmaceuticals), allows insight into the metabolic processes in the body. Introducing new radiopharmaceuticals, the range of possibilities that PET can offer not only in oncology, but also in cardiology, neurology, and psychiatry was expanded. The aim of this paper is to present the new PET radiopharmaceuticals in dementia diagnostics. Dementia represents an acquired and persistent disorder of intellectual functions with a deficit in at least three of the following intellectual functions: memory, language, visuospatial abilities, personality and behavior, and other cognitive abilities, such as abstract thinking, computing, reasoning, and planning. Radiopharmaceuticals used in research and diagnosis of patients suffering from dementia are divided according to the target they are supposed to visualize into radiopharmaceuticals for: representation of the energetic metabolism of the brain (glucose/hexokinase transport), visualization of the incorrectly configured proteins (β-amyloid plaques, tau, α-synuclein), representation of the neurotransmitter systems, representation of the synaptic density (synaptic vesicle glycoprotein 2A (SV2A) labeled), and representation of the neuroinflammation. Studies with the PET radiopharmaceuticals for the new pathophysiological processes can result in earlier diagnosis and better classification of the neurodegenerative disorders, as well as in choosing appropriate therapeutic procedure for each individual patient and in improved monitoring of the effects of therapy.
References
Petrović N: Methods of Nuclear Medicine in Neurology, in Nuclear Medicine, Šobić Šaranović D, Artiko V, eds. Faculty of Medicine, University of Belgrade 2020. [Petrović N: Metode nuklearne medicine u neurologiji, u Nuklearna medicina, urednici: Šobić Šaranović D, Artiko V, Medicinski fakultet Univerziteta u Beogradu 2020.]
Townsend DW. Basic Science of PET and PET/CT. U: Valk PE, Delbeke D, Bailey DL, Townsend DW, Maisey MN, eds. Positron Emission tomography: Clinical practice. United Kingdom: Springer London; 2006.
Dementia in Neurology, Kostić S. V, ed. Faculty of Medicine, University of Belgrade 2020. [Demencije u Neurologija, urednik Kostić S. V, Medicinski fakultet Univerziteta u Beogradu 2016.]
World Health Organization, Alzheimer’s Disease International. Dementia: a public health priority. Geneva; 2012.
Budanec M, Grošev D, Ivančević D, Kasal B, Lukinac L, Popović S, et al. Foundations. In Clinical Nuclear Medicine, Dodig D, Kusić Z, eds. 2. edition. Zagreb: Medicinska naklada; 2012. [Budanec M, Grošev D, Ivančević D, Kasal B, Lukinac L, Popović S, i dr. Osnove. U: Dodig D, Kusić Z, urednici. Klinička nuklearna medicina. 2. izd. Zagreb: Medicinska naklada; 2012.]
Sokoloff L. Relation between physiological function and energy metabolism in the central nervous system. J Neurochem. 1977; 29(1): 13–26.
Herholz K. PET studies in dementia. Ann Nucl Med. 2003; 17(2) :79–89. 150
Herholz K, Carter S, Jones M. Positron emission tomography imaging in dementia. Br J Radiol. 2007; 80(Special Issue 2): S160-7.
Gaugler J, James B, Johnson T, Scholz K, Weuve J. 2015 Alzheimer’s Disease Facts and Figures. Chicago: Alzheimer’s Association; 2015. 18
Smailagic N, Vacante M, Hyde C, Martin S, Ukoumunne O, Sachpekidis C, F‐FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2015 Jan; 2015(1): CD010632.Published online 2015 Jan 28. doi: 10.1002/14651858.CD010632.pub2
Silverman DHS, Small GW, Chang CY, Lu CS, de Aburto MAK, Chen W, et al. Positron Emission Tomography in Evaluation of Dementia: Regional Brain Metabolism and Long-term Outcome. JAMA. 2001; 286(17): 2120.
Bohnen NI, Djang DSW, Herholz K, Anzai Y, Minoshima S. Effectiveness and Safety of 18F-FDG PET in the Evaluation of Dementia: A Review of the Recent Literature. J Nucl Med. 2012; 53(1): 59–71.
Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004; 55(3): 306-19.
Rabinovici GD, Furst AJ, O’Neil JP, Racine CA, Mormino EC, Baker SL, et al. 11CPIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007; 68(15): 1205-12.
Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008; 29(10): 1456-65.
Shin J, Kepe V, Barrio JR, Small GW. The Merits of FDDNP-PET Imaging in Alzheimer’s Disease. J Alzheimeraposs Dis. 2011; (s3): 135-45.
Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE. Amyloid imaging in Alzheimer’s disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry. 2012; 83(9): 923-6.
Hatashita S, Yamasaki H, Suzuki Y, Tanaka K, Wakebe D, Hayakawa H. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2014; 41(2): 290-300.
Landau SM, Thomas BA, Thurfjell L, Schmidt M, Margolin R, Mintun M, et al. Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging. 2014; 41(7): 1398-
Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Phase 3 Trial of Flutemetamol Labeled With Radioactive Fluorine 18 Imaging and Neuritic Plaque Density. JAMA Neurol. 2015; 72(3): 287.
S Patel, PN Tariot Pharmacologic models of Alzheimer's disease Psychiatr Clin North Am. 1991; 14: 287-308.
WJ Krall, JJ Sramek, NR Cutler Cholinesterase inhibitors: A therapeutic strategy for Alzheimer disease Ann Pharmacother. 1999; 33: 441-50.
P Raina, P Santaguida, A Ismaila, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline Ann Intern Med. 2008; 148: 379-97.
RT Bartus, RL Dean III, B Beer, et al. The cholinergic hypothesis of geriatric memory dysfunction Science. 1982; 217: 408-14.
R Roy, F Niccolini, G Pagano, et al. Cholinergic imaging in dementia spectrum disorders Eur J Nucl Med Mol Imaging. 2016; 43: 1376-86.
T Butler, P Harvey, A Deshpande, et al. Basal forebrain septal nuclei are enlarged in healthy subjects prior to the development of Alzheimer's disease Neurobiol Aging. 2018; 65: 201-4.
ML Müller, NI Bohnen Cholinergic dysfunction in Parkinson's disease Curr Neurol Neurosci Rep. 2013; 13:
M Aghourian, C Legault-Denis, JP Soucy, et al. Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV Mol Psychiatry. 2017; 22: 1531-8. 151
M Petrou, KA Frey, MR Kilbourn, et al. In vivo imaging of human cholinergic nerve terminals with (-)-5-18F-fluoroethoxybenzovesamicol: Biodistribution, dosimetry, and tracer kinetic analyses J Nucl Med. 2014; 55: 396-404.
KL Leenders, EP Salmon, P Tyrrell, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease Arch Neurol. 1990; 47: 1290-8.
V Marshall, D Grosset Role of dopamine transporter imaging in routine clinical practice Mov Disord. 2003; 18: 1415-23. 18
XS Hu, N Okamura, H Arai, et al. F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies Neurology. 2000; 55: 1575-7.
JO Rinne, M Laine, V Kaasinen, et al. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia Neurology. 2002; 58: 1489-93.
M Itoh, K Meguro, T Fujiwara, et al. Assessment of dopamine metabolism in brain of patients with dementia by means of F-fluorodopa and PET Ann Nucl Med. 1994; 8: 245-51.
R Hilker, AV Thomas, JC Klein, et al. Dementia in Parkinson disease: Functional imaging of cholinergic and dopaminergic pathways Neurology. 2005; 65: 1716-22.
JL Robinson, L Molina-Porcel, MM Corrada, et al. Perforant path synaptic loss correlates with cognitive impairment and Alzheimer's disease in the oldest-old Brain. 2014; 137: 2578-87.
A Delva, D Van Weehaeghe, M Koole, et al. Loss of presynaptic terminal integrity in the substantia nigra in early Parkinson's disease Mov Disord. 2020; 35: 1977-86.
SE Holmes, D Scheinost, SJ Finnema, et al. Lower synaptic density is associated with depression severity and network alterations Nat Commun. 2019; 10: 1529.
J Mercier, L Provins, A Valade Discovery and development of SV2A PET tracers: Potential for imaging synaptic density and clinical applications Drug Discov Today Technol. 2017; 25: 45-55.
H Akiyama, S Barger, S Barnum, et al. Inflammation and Alzheimer's disease Neurobiol Aging. 2000; 21: 383-
E Gyengesi, G Münch In search of an anti-inflammatory drug for Alzheimer disease Nat Rev Neurol. 2020; 16:
A Serrano-Pozo, ML Mielke, T Gómez-Isla, et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease Am J Pathol. 2011; 179: 1373-84.
RB Banati, J Newcombe, RN Gunn, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: Quantitative in vivo imaging of microglia as a measure of disease activity Brain. 2000; 123: 2321-37. 11
KK Yoder, K Nho, SL Risacher, et al. Influence of TSPO genotype on C-PBR28 standardized uptake values J Nucl Med. 2013; 54: 1320-2. 11
M Ikawa, TG Lohith, S Shrestha, et al. C-ER176, a radioligand for 18-kDa translocator protein, has adequate sensitivity to robustly image all three affinity genotypes in human brain J Nucl Med. 2017; 58: 320-5.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Veljko Ajdinović, Boris Ajdinović
This work is licensed under a Creative Commons Attribution 4.0 International License.
